The research compound in Wegovy^®

Wegovy^® is a chronic weight management medicine from Novo Nordisk. Its active compound is Semaglutide — which is what this catalogue supplies, as a research material.

This is not Wegovy^®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Semaglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Wegovy^® is a trademark of Novo Nordisk, referenced here only to identify the compound.

Wegovy is Novo Nordisk’s brand for semaglutide in weight management, at higher doses than the same compound carries under the Ozempic brand for diabetes.

The molecule is unchanged between the two: a long-acting GLP-1 receptor agonist designed to resist DPP-4 degradation and bind strongly to albumin.

Semaglutide is listed here as a research material with batch documentation, not as the branded medicine.

Semaglutide in this catalogue

Other brands using Semaglutide

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.